Antibody-drug conjugates in prostate cancer: current landscape and future directions
Therapeutic Advances in Medical Oncology
Published online on March 14, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic option, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. While initially developed for hematologic and select solid malignancies, advances in ...
Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic option, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. While initially developed for hematologic and select solid malignancies, advances in ...